Paul Agapow
Chief Scientific Officer, Bayezian | Machine Learning in Clinical Development & Regulated Workflows
Paul Agapow is Chief Scientific Officer at Bayezian, which describes itself as the intelligence layer for clinical development.
He came to biology late and by an unusual route, having read a Time magazine cover story on Genentech in rural Australia and realized the work could be a career. A long path through academia and consulting followed before he settled into pharma, drug development and AI. He was primarily responsible for canceling a large clinical trial, a decision he describes as straightforward because the data was in front of him.
His work covers clinical data, machine learning in regulated workflows, and the reasons biology resists the assumptions AI is built on. He is known for distinguishing what AI can do in biology from what it is sold as doing, and on Open Door Salon he estimated that about a third of what the industry is building today will still be standing in five years.
Frequently Asked Questions About Paul Agapow
Who is Paul Agapow?
Paul Agapow is Chief Scientific Officer at Bayezian, which describes itself as the intelligence layer for clinical development. He came to biology late, by way of a Time magazine cover story on Genentech he read in rural Australia, and spent years across academia and consulting before settling into pharma, drug development and AI.
What is Paul Agapow an expert in?
Paul Agapow works on clinical data, machine learning in regulated drug development workflows, and the reasons biology resists the assumptions AI is built on. He is known for distinguishing what AI can do in biology from what it is sold as doing.
How does Paul Agapow evaluate claims about AI in biology?
Paul Agapow starts from the nature of the data. He argues that biological data is something being discovered rather than invented, and that it is contingent on which cells, which patients and the conditions of collection, which breaks assumptions machine learning carries in from domains that can be observed completely. On that basis he treats a digital twin as a copy of a process already understood, and therefore as something that cannot stand in for a patient in a trial.
What organizations is Paul Agapow associated with?
Paul Agapow is Chief Scientific Officer at Bayezian, a company working on clinical development intelligence. His earlier career spanned academia, consulting and pharmaceutical drug development.
On Open Door Salon
“Nindhana Paranthaman and Paul Agapow on What AI Delivered in Clinical Development”
Nindhana Paranthaman & Paul Agapow · September 23, 2026
Topics
Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.
Subscribe on Substack →